[1]潘雪刁,何冰,王桂香,等.肺癌特异性结合多肽的体外筛选和鉴定[J].中国药理学通报,2013,(03):342-346.
 PAN Xue diao,HE Bing,WANG Gui xiang,et al.Screening and identifying the peptide specifically binding to lung cancer by using phage display in vitro[J].Chinese Pharmacological Bulletin,2013,(03):342-346.
点击复制

肺癌特异性结合多肽的体外筛选和鉴定()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2013年03期
页码:
342-346
栏目:
论著
出版日期:
2013-03-25

文章信息/Info

Title:
Screening and identifying the peptide specifically binding to lung cancer by using phage display in vitro
作者:
潘雪刁1何冰1王桂香1刘金泳2曹成明2臧林泉123
广东药学院1. 药科学院药理系、2. 药科学院新药筛选与药效学评价中心,广东 广州510006; 3. 广东省分子流行病学重点实验室,广东 广州510310
Author(s):
PAN Xuediao1 HE Bing1 WANG Guixiang1LIU Jinyong2 CAO Chengming2 ZANG Linquan123
1.Dept of Pharmacology; 2.New Drug Screening and Pharmacodynamics Evaluation Center, College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou510006,China; 3.Guangdong Key Laboratory of Molecular Epidemiology, Guangdong Pharmaceutical University, Guangzhou510310,China
关键词:
肺癌噬菌体展示技术多肽减性筛选NCIH1299细胞肽库
Keywords:
lung cancer phage display polypeptide subtractive screening NCI H1299 cells peptide library
分类号:
R341.6;R394.3;R734.204;R734.205;R977.6
文献标志码:
A
摘要:
目的应用噬菌体随机肽库技术筛选出与肺癌细胞特异性结合的多肽。方法以人肺癌细胞NCIH1299为靶细胞,人胚肺细胞MRC5为吸附细胞,对噬菌体随机12肽库进行3轮全细胞减性筛选后,随机挑取噬菌体克隆进行ELISA鉴定;对亲和力较高的阳性克隆进行DNA测序并翻译为氨基酸序列;化学合成异硫氰酸荧光素标记的多肽(FITCZS5),采用细胞和组织免疫荧光法鉴定FITCZS5与肺癌细胞的亲和力及特异性。结果通过3轮减性筛选后,与NCIH1299细胞结合的噬菌体克隆得到有效的富集;ELISA结果显示5号克隆对NCIH1299细胞亲和力最高,将其命名为Phage ZS5;测序结果显示Phage ZS5所表达的多肽序列在国内外均未见报道,细胞及组织免疫荧光实验结果显示FITCZS5 对肺癌细胞及组织具有较高的亲和力和特异性。结论应用噬菌体随机肽库技术筛选到肺癌靶向性多肽ZS5,为肺癌的靶向治疗和诊断奠定基础。
Abstract:
AimIn vitro phage display was used to screen and identify a polypeptide specifically targeting lung cancer cells. MethodsThe lung cancer NCIH1299 cell line and the normal lung MRC5 cell line were used for the subtractive screening in vitro with a phage display12 peptide library at 37℃. After three rounds of panning, a group of phage clones specifically binding to the NCIH1299 cells were obtained, then the affinity of these clones binding to the targeted cells was studied by cellbased ELISA. The phage clones with high affinity was sequenced, thus the amino acid sequence was deduced and the peptide was synthesized and identified by immunofluorescence. ResultsAfter three rounds of panning, there was an obvious enrichment for the phage clones specifically binding to the NCIH1299 cells. A phage clone named phage ZS5 with high specificity and affinity to NCIH1299 cells was identified by a cellbased ELISA. More importantly, the synthetic FITClabeled peptide ZS5, which corresponded to the sequence of the inserted fragment of phage ZS5, demonstrated a high specificity to lung cancer cells and tissues, but not to normal lung cell and tissue samples, or other different cancer cells. ConclusionThe peptide ZS5 specifically binding to lung cancer has been screened from phage display peptide libraries , which can be used for targeted drug delivery in therapy or in early diagnosis of lung cancer.

参考文献/References:

[1]Jemal A, Bray F, Center M M, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2]虞永峰, 陆舜. 表皮生长因子受体和血管内皮细胞生长因子受体之外肺癌靶向治疗新进展 [J]. 肿瘤, 2010,30(8):706-10.
[2]Yu Y F, Lu S. Targeted therapies for lung cancer beyond antiepidermal growth factor receptors and antivascular endothelial cell growth factor receptors:exploring a new frontier [J]. Tumor, 2010,30(8):706-10.
[3]潘峰,田静,张旭超,潘跃银. 舒尼替尼对EGFR TKI 抵抗的A549细胞株增殖抑制作用及机制研究 [J]. 中国药理学通报, 2011,27(8):1121-5.
[3]Pan F, Tian J, Zhang X C, Pan Y Y. Inhibitory effect of sunitinib on EGFR TKIresistant human nonsmall cell lung cancer cell line A549 and its mechanism [J]. Chin Pharmacol Bull, 2011,27(8):1121-5.
[4]张涛,单利,张东明. 分子靶向药物应用于非小细胞肺癌维持治疗的研究进展 [J]. 中国肺癌杂志, 2010,13(11):1070-3.
[4]Zhang T, Shan L, Zhang D M. Advances of molecular targeted drugs used in maintenance therapy of nonsmall cell lung cancer [J]. Chin J Lung Cancer, 2010,13(11): 1070-3.
[5]王健,王秀问,王亚伟,等. 奥曲肽紫杉醇偶联物靶向治疗小细胞肺癌的实验研究 [J]. 山东大学学报(医学版), 2011,49(3):27-32.
[5]Wang J, Wang X W, Wang Y W,et al. Paclitaxeloctreotide conjugates inhibit growth of human small cell lung cancer cells [J]. J Shandong Univ (Health Sci), 2011, 49(3):27-32.
[6]张晓艳,孙立新,容雁,等. 功能性单克隆抗体40E11靶向治疗肺癌的实验研究 [J]. 中华肿瘤防治杂志, 2012,19(6):401-5.
[6]Zhang X Y, Sun L X, Rong Y, et al. Targeting therapy of lung cancer using functional monoclonal antibody 40E11 [J]. Chin J Cancer Prev Treat, 2012,19 (6):401-5.
[7]Goenaga A L, Zhou Y, Legay C, et al. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies [J]. Mol Immunol, 2007, 44(15): 3777-88.
[8]Elayadi A N, Samli K N, Prudkin L, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer [J]. Cancer Res, 2007, 67(12): 5889-95.
[9]Sergeeva A, Kolonin M G, Molldrem1 J J, et al. Display technologies: application for the discovery of drug and gene delivery agents[J]. Adv Drug Deliv Rev, 2006, 58(15): 1622-54.
[10]张旭,彭健,王顺伟,等. 噬菌体随机肽库对肝癌细胞特异性结合短肽的筛选及鉴定 [J]. 第四军医大学学报, 2008,29(17):1544-7.
[10]Zhang X, Peng J, Wang S W, et al. Screening and identification of hepatocellular carcinoma cell specific binding peptides using phage display peptide library [J]. J Fourth Mil Med Univ, 2008,29(17):1544-7.
[11]Scott J K, Smith G P. Searching for peptide ligands with an epitope library [J].Science,1990, 249(4967):386-90.
[12]丁宁,肖慧,高巨,等. 晚期糖基化终产物受体胞外段的原核表达及其相互作用蛋白的筛选[J]. 中国药理学通报, 2009,25(4):492-6.
[12]Ding N, Xiao H, Gao J, et al. Prokaryotic expression of receptor for advanced glycation end product and screening of its interaction proteins[J]. Chin Pharmacol Bull, 2009,25(4):492-6.

相似文献/References:

[1]冯文彬,潘雪刁,周捷,等.利用肺癌特异性结合多肽ZS6筛选肺癌相关标志物[J].中国药理学通报,2010,(01):44.
 FENG Wen bin,PAN Xue diao,ZHOU Jie,et al.Screening of tumor mark for the lung cancer by using peptide ZS6[J].Chinese Pharmacological Bulletin,2010,(03):44.
[2]刘华钢,秦三海,刘丽敏,等.鹅掌楸碱银配合物体外诱导肺癌SPCA1细胞凋亡及其机制的研究[J].中国药理学通报,2008,(11):0.
 LIU Hua gang,QIN San hai,LIU Li min,et al.Apoptosisinducing effects of AgLA2 on SPCA1 cells and its mechanism in vitro[J].Chinese Pharmacological Bulletin,2008,(03):0.
[3]石磊,潘雪刁,王军业,等.噬菌体随机肽库淘选肺癌细胞NCIH1299特异性结合多肽[J].中国药理学通报,2009,(03):0.
 SHI Lei,PAN Xue diao,WANG Jun ye,et al.Panning and identification of lung cancer cell line NCIH1299 specific peptide from a phage display peptide library[J].Chinese Pharmacological Bulletin,2009,(03):0.
[4]郝吉庆,孙耕耘,沈玉先.氯美昔布抗肺癌细胞增殖作用的机制探讨[J].中国药理学通报,2009,(07):0.
 HAO Ji qing,SUN Geng yun,SHEN Yu xian.Mechanisms of lumiracoxib on antitumor in human lung cancer cells[J].Chinese Pharmacological Bulletin,2009,(03):0.
[5]彭蕾,薛仁宇,顾振纶,等.冬凌草甲素对人肺腺癌细胞株SPCA1增殖和凋亡的影响[J].中国药理学通报,2010,(04):558.
 PENG Lei,XUE Ren yu,GU Zhen lun,et al.The inhibitory and apoptosis effect of Oridonin on human lung adenocarcinoma SPCA1[J].Chinese Pharmacological Bulletin,2010,(03):558.
[6]熊飞,詹瑧,唐于平,等.PI3K/Akt信号转导通路在非小细胞肺癌中的作用[J].中国药理学通报,2010,(10):1264.
 XIONG Fei,ZHAN Zhen,TANG Yu ping,et al.The effect of PI3K/Akt signal transduction pathway in nonsmall cell lung cancer[J].Chinese Pharmacological Bulletin,2010,(03):1264.
[7]潘 峰,田 静,张旭超,等.舒尼替尼对EGFR TKI抵抗的A549 细胞株增殖抑制作用及机制研究[J].中国药理学通报,2011,(08):1121.
 PAN Feng,TIAN Jing,ZHANG Xu-chao,et al. Inhibitory effect of sunitinib on EGFR TK Iˉresistant hum an nonˉsm all cell lung cancer cell line A549and itsm echanism[J].Chinese Pharmacological Bulletin,2011,(03):1121.
[8]李济元,王卫华,张彦梅,等.白藜芦醇对肺腺癌细胞增殖和CXCR4表达的影响[J].中国药理学通报,2012,(04):588.
 LI Ji yuan,WANG Wei hua,ZHANG Yan mei,et al.Effects of resveratrol on proliferation and expression of CXCR4 in human lung adenocarcinoma A549 cells[J].Chinese Pharmacological Bulletin,2012,(03):588.
[9]韩冬,王贵佐,李满祥.腺苷酸活化蛋白激酶在肺部疾病中的作用[J].中国药理学通报,2013,(04):460.
 HAN Dong,WANG Gui zuo,LI Man xiang.Role of AMPK in pulmonary diseases[J].Chinese Pharmacological Bulletin,2013,(03):460.
[10]李梦姣,等.蓝萼甲素对人肺癌A549细胞的作用及其机制[J].中国药理学通报,2013,(06):882.
 LI Meng jiao,GU Zhen lun,DONG Li xia,et al.Effects of glaucocalyxin A on human lung cancer A549 cells and its mechanism[J].Chinese Pharmacological Bulletin,2013,(03):882.

备注/Memo

备注/Memo:
收稿日期:2012-12-12,修回日期:2013-01-27 基金项目:国家自然科学基金资助项目(No 81102465);国家科技重大专项“重大新药创制”资助项目(No 2011zx0910200131),国家高技术研究发展计划(863计划)资助项目(No 2012AA020304);广东省科技计划项目(No 2010B031500034);广州市科技计划项目(No 2010JE091);中山市科技局项目(No 2009H018);广东药学院中青年骨干教师专项课题 作者简介:潘雪刁(1980-),女,硕士,讲师,研究方向:肿瘤药理学及多肽药物,Tel:02039352123,Email:panxuediao@126.com; 臧林泉(1965-),男,博士,教授,研究方向:肿瘤药理学及多肽药物,通讯作者,Tel:02039352123,Email:zanglq@163.com
更新日期/Last Update: 2013-03-25